Table 3.
Summary of study characteristics and costs per DALY averted for interventions targeting children
| References | Publication year | Country/region | Malaria intervention | Main data sources | Life tables source | Cost-effectiveness threshold used | Cost-effectiveness ratio (cost per DALY averted) | DALYs averted per $ 1 million spent on intervention |
|---|---|---|---|---|---|---|---|---|
| [1] | 2000 | Tanzania | Chemoprophylaxis | Clinical trial Passive case detection Survey |
Model life table West 25 and 26 | US$30–US$ 150 | $11–12 | 86,956 |
| [2] | 2008 | Togo | LLITNs | Regional estimates Financial records and interviews |
Togo life tables | US$30–US$ 150 | $16.39 | 61,013 |
| [3] | 2009 | Mozambique and Tanzania | Intermittent preventive treatment in infants (IPTi) | Expanded program on immunization | East African life table | US$ 30 and US$ 150 | $3.70 in Tanzania | 270,270 |
| $11.20 in Mozambique | 89,286 | |||||||
| [4] | 2010 | Multi-country | Intermittent preventive Treatment (ITP) |
Model | Country-specific | US$ 202 | $2.90–$39.63 | 47,170 |
| [5] | 2010 | Pre-referral rectal artenusate | Sub-Saharan Africa life table | 1–3 times GDP per capita | I$77c (at full uptake) | 12,987 | ||
| [6] | 2011 | Multi-country (Tanzania, Uganda, Nigeria) | Parenteral artenusate | Clinical trials | Country-specific (3 countries) | US$30–US$ 150 | $123a | 8130 |
| [7] | 2011 | Model | Intermittent preventive treatment in infants (IPTi) and children (IPTc) |
Simulation model Clinical trials |
East African life table | US$ 37–US$223 | <$100 | <10,000 |
| [8] | 2014 | Africa | Dihydroartemisinin–piperaquine (DP) and artemether–lumefantrine (AL) | Randomised trials | WHO African sub-region life table | Not stated | $0.96 per child over one yearb | Not applicable |
| [9] | 2014 | Malawi | Vaccines and Lon lasting insecticide treated nets (LLITNs) | Published sources | Malawian life table | 1–3 times GDP per capita | $145.03 (from a health service perspective | 6895 |
| [10] | 2014 | Tanzania | Dihydroartemisinin–piperaquine Artemether–lumefantrine |
Published studies Health facility |
Tanzanian life table | US$ 30–US$ 150 GDP per capita |
$12.40–12.54 | 80,192 |
aThese were DALYs averted after treatment with artenusate compared to quinine as a baseline
bFirst-line treatment with dihydroartemisinin–piperaquine (DP) compared to artemether–lumefantrine saved $0.96
cI$ stands for international dollars